Stocks and Investing Stocks and Investing
Fri, August 11, 2023

Andrew Fein Reiterated (AMLX) at Strong Buy and Held Target at $50 on, Aug 11th, 2023


Published on 2024-10-28 05:51:15 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Reiterated "Amylyx Pharmaceuticals, Inc." (AMLX) at Strong Buy and Held Target at $50 on, Aug 11th, 2023.

Andrew has made no other calls on AMLX in the last 4 months.



There are 2 other peers that have a rating on AMLX. Out of the 2 peers that are also analyzing AMLX, 0 agree with Andrew's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Andrew


  • Chris Shibutani of "Goldman Sachs" Upgraded from Hold to Strong Buy and Increased Target to $49 on, Monday, July 24th, 2023
  • Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Decreased Target to $50 on, Monday, May 15th, 2023
Contributing Sources